

1 Bioprocessing and Biological Engineering

2 **Improved Yield of rhEPO in CHO Cells with Synthetic 5' UTR**

3

4 Alan Costello¹, Nga T. Lao¹, Niall Barron^{2,3*} & Martin Clynes^{1*}

5 ** These authors contributed equally*

6

7 ¹National Institute for Cellular Biotechnology, Dublin City University, Dublin, D09 NR58, Ireland.

8 ²National Institute for Bioprocessing Research and Training, Dublin, A94 X099, Ireland.

9 ³University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland.

10

11 **Correspondence should be addressed to:** Alan Costello, National Institute for Cellular
12 Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland, **e-mail.**
13 alan.costello23@mail.dcu.ie, **tel.** +35317006246.

14

15

1 **Abstract**

2 The impact of local structure on mRNA translation is not well-defined pertaining to the 5' UTR. Reports
3 suggest structural remodelling of the 5' UTR can significantly influence mRNA translation both in *cis*
4 and *trans* however a new layer of complexity has been applied to this model with the now known
5 reversible post-transcriptional chemical modification of RNA. *N*⁶-methyladenosine (m⁶A) is the most
6 abundant internal base modification in mammalian mRNA. It has been reported that mRNAs harbouring
7 m⁶A motifs in their 5' UTR have improved translation efficiency. The present study evaluated the
8 addition of putative m⁶A motifs to the 5' UTR of a model recombinant human therapeutic glycoprotein,
9 Erythropoietin (EPO), in a direct comparison with an A to T mutant and a no adenosine control. The
10 m⁶A construct yielded significantly improved EPO titer in transient batch culture over no adenosine
11 and m⁶T controls by 2.84 and 2.61-fold respectively. This study highlights that refinement of transgene
12 RNA elements can yield significant improvements to protein titer.

13 **Key words:** 5' UTR, *N*⁶-methyladenosine, m⁶A, CHO, Bioprocessing, Synthetic biology

14

1 **Introduction**

2 RNA forms complex secondary and tertiary structures with known examples of structure-directed
3 function (Leppik et al., 2017). Predicting the impact of cis-regulatory sequences of non-coding scripts,
4 such as un-translated regions (UTR), on mRNA translation in higher eukaryotes remains a challenge.
5 Recent growing appreciation for functional heterogeneity between eukaryotic ribosomal complexes and
6 its associated proteins (Simsek et al., 2017; Shi et al., 2017) coupled with evidence of mRNA-structure-
7 influenced translation raises the question: how much regulatory potential is owed to mRNA structure
8 and structure-directed recruitment of RNA-binding protein (RBP) translation-driving factors?
9 (Topisirovic et al., 2011; Pichon et al., 2012; Manning & Cooper, 2016). For this reason, the structure
10 of UTR sequence in transgene expression cassettes may offer “playgrounds” for synthetic engineering
11 of transgene expression. Early studies to synthetically remodel the 5’ un-translated region (UTR) of
12 transgene mRNA (Kozak, 1986; Grens & Scheffler, 1990) indicated highly-stable GC-rich secondary
13 duplexes ($\Delta G = -50$ kcal/ mol) upstream of the initiation AUG triplet prevented scanning of the 40S
14 ribosome subunit leading to reduced protein yield. And complete removal 5’ UTR sequence comes with
15 the caveat of omitting known translational enhancer elements, impacting negatively on mRNA
16 translation (Stein et al., 1998).

17 Reversible epigenetic modifications to both genomic DNA (Suzuki & Bird, 2008) and histone proteins
18 (Strahl & Allis, 2000) have been known to influence gene expression and regulate cellular behaviour.
19 Recent discovery of the intermediary member of the central dogma, RNA, having similar reversible
20 chemical tuning has redefined how RNA metabolism is viewed (He, 2010; Fu et al., 2014). The most
21 abundant internal mRNA modification in mammalian cells is N^6 -methyladenosine (m^6A) (Wei et al.,
22 1975). Transcriptome analysis of human cells and mouse tissue have revealed m^6A consensus motifs to
23 be in the form of DRACH, [D=G/A/U] [R=G>A] m^6AC [H=U>A>C]. m^6A motifs are present in coding
24 regions, 3’ or 5’ UTRs of mRNAs (Dominissini et al., 2012; Meyer et al., 2012) and in non-coding RNA
25 (ncRNA) scripts (Wei et al., 1975) with enriched abundance at stop codons (Huang et al., 2018). This
26 discovery of RNA chemical tuning adds a new layer of complexity to our understanding of how UTR
27 sequence and structures can regulate mRNA translation.

28 In mammalian cells, m^6A is generated by a multicomponent methyltransferase “writer”-complex
29 comprised of; METTL3, METTL14 and WTAP (Liu et al., 2014; Ping et al., 2014). This reaction is
30 reversible with the “eraser” proteins FTO (Jia et al., 2011) and ALKBH5 (Zheng et al., 2013). Both
31 writer and eraser modifications occur in the cell nucleus. The molecular mechanisms underpinning how
32 m^6A motifs are recognised by different known m^6A -RNA binding proteins (RBPs) and regulate m^6A -
33 RNA fate is still poorly understood. It has been reported that the stability of m^6A -modified mRNA is
34 under dynamic regulation by three cytoplasmic “reader” proteins of the YTH domain family, YTHDF1-
35 3 (Wang et al., 2015). The crystal structure of YTHDF2s YTH domain revealed the m^6A recognition

1 site (Zhu et al., 2014) as an aromatic cage (Li et al., 2014). The m⁶A reader YTHDF2 recognises m⁶A
2 marked mRNA and selectively reduces the stability of such messages (Wang et al., 2014). The
3 mechanism by which YTHDF2 destabilises mRNA harbouring m⁶A was revealed to be mediated by
4 accelerated transcript deadenylation via the CCR4-NOT complex (Du et al., 2017). While YTHDF2
5 controls the turnover of m⁶A containing mRNA, YTHDF1-mediates enhanced translational efficiency
6 of m⁶A containing scripts (Wang et al., 2015). This mechanism of epigenetic post-transcriptional
7 control permits the cell to prioritise the protein synthesis of m⁶A marked mRNAs. Contrary to the
8 mRNA-decay-promoting action of YTHDF2, IGF2BPs 1-3 have been identified as a family of m⁶A
9 readers that promote target mRNA stability and translation (Huang et al., 2018). The consensus m⁶A
10 recognition motif differs slightly between YTHDF and IGF2BPs with the nucleotide at position -3 to
11 the A being A/U for YTHDF and U/C for IGF2BP. This selective recognition of different m⁶A-RBP
12 families adds to the complexity of post-transcriptional epigenetic regulation.

13 Independent studies have demonstrated that the presence of consensus putative m⁶A motifs in the 5'
14 UTR of transgene mRNA significantly improves the transcript's translation efficiency in both cap-
15 independent (Meyer et al., 2015; Yang et al., 2017) and cap-dependent (Wang et al., 2015) manners in
16 human cells. Moreover, the location of a single m⁶A motif in the 5' UTR significantly impacts the
17 mRNAs' translation with close-proximity to the gene start codon giving the highest protein production
18 (Meyer et al., 2015). An understudied area in industrial biotechnology has been improving the protein
19 coding potential of transgene mRNA in mammalian production hosts. While codon optimisation has
20 improved the rate of elongation, selectively biasing the host to initiate transgene protein synthesis and
21 or increase mRNA stability could significantly enhance recombinant protein yields.

22

23 **Materials and Methods**

24 **Plasmid construction and transcript analysis**

25 The human EPO open reading frame was synthesised (GenScript) with one of; a putative m⁶A -
26 GGACTAAAGCGGACTTGT, m⁶T - GGTCTAAAGCGGTCTTGT, or no adenosine control
27 sequence - CGGTGCCGGTGC, taken from (Yang et al., 2017). These constructs were cloned into in a
28 pcDNA-3.1 (+) Hygromycin (Invitrogen) backbone using HindIII and EcoRV sites. RNA secondary
29 structure was predicted with RNAFold ([http://rna.tbi.univie.ac.at/cgi-](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi)
30 [bin/RNAWebSuite/RNAfold.cgi](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi)). Tertiary RNA structure was predicted using RNAComposer
31 (<http://rnacomposer.cs.put.poznan.pl/>) and sequence features highlighted using PyMOL V2.2.

32 **Cell culture and transfection**

33 CHO-K1 (ATCC) were grown in Balan CD Growth A (Irvine Scientific) with (2.52g L⁻¹) polyvinyl
34 alcohol (PVA), and sub-cultured every 72-96hrs. Cultures were maintained in a Climo-Shaker

1 (Kühner), 37°C, 80% humidity and 5% CO₂ with routine seeding at 2x10⁵ cells mL⁻¹ in 50mL spin tube
2 (TPP). Cell growth and viability was monitored using the Guava EasyCyte ViaCount programme
3 (Merck Millipore). Prior to transfection, cells were washed twice with CHO S SFM II (Gibco) and
4 seeded at 1x10⁶ cells mL⁻¹ in 2 mL of CHO S SFM II. Transfection was performed in accordance with
5 the MIRUS Transit 2X protocol. In brief, a complex of a [1:2] ratio µg pDNA to µL transfection reagent
6 was formed in 100µL of pre-warmed, 37°C, CHO S SFM II, for 30mins. Transfection complexes were
7 then added to the cell suspension and incubated for 24hrs. All transfections were done using a ratio of
8 1µg of plasmid DNA per 1x10⁶ cells. 24hrs post transfection the cultures were washed twice in Balan
9 CD Growth A with PVA and seeded at 3x10⁵ cells mL⁻¹ in triplicate 5mL cultures.

10 **RNA isolation**

11 Transfected cells were harvested by centrifugation at 91 x g for 5 minutes. Cell pellets were washed in
12 phosphate buffered saline (PBS) and centrifuged again. Total RNA was isolated from 1-5x10⁶ cells
13 using 1mL of Tri-reagent (Ambion) with no divergence from the manufacturer's protocol. RNA
14 quantification and quality were evaluated by NanoDrop (Thermo Scientific). To remove contaminating
15 plasmid DNA, RNA samples were treated with DNase I (Sigma Aldrich) as per manufacturer's
16 protocol.

17 **qPCR**

18 Reverse transcription of total RNA was performed with the High Capacity cDNA Reverse Transcription
19 Kit (Applied Biosystems) in accordance with the manufacture's protocol. RT-qPCR was performed on
20 an AB7500 (Applied Biosystems) using Fast SYBR Green Master Mix (Applied Biosystems). The 2X
21 SYBR master mix was combined with 20 ng of cDNA, 200 nM forward and reverse primers, and water
22 made up to 20 µL final reaction volume. Each biological replicate sample was run in technical triplicate
23 wells. Primer sequences used are as follows; Gapdh FW - TGGCTACAGCAACAGAGTGG, Gapdh
24 RV - GTGAGGGAGATGATCGGTGT, hEPO FW - ACTTGTCTCGAGATGGGGGT, hEPO RV -
25 AGGTACCTCTCCAGGACTCG, HYG RW - ATGCTCCGCATTGGTCTTGA, HYG RV -
26 ATTTGTGTACGCCGACAGT. Relative quantification of PCR products was calculated using the
27 ddCt method with Gapdh as an endogenous control and HYG as a control of transfection efficiency.
28 Error was calculated as the standard deviation of three biological replicates.

29 **ELISA**

30 Secreted EPO was quantified by enzyme linked immunosorbent assay (ELISA) of cell culture
31 supernatant. Culture supernatant was harvested by centrifugation of cell suspension at 91 x g for 5
32 minutes. Nunc-Immuno™ MicroWell™ 96 well solid plates (M9410 Sigma-Aldrich) were coated with
33 100 µL of capture antibody MAB-287 (R&D Systems), diluted 1:500 in coating buffer (C3041-50CAP)
34 (Sigma-Aldrich) for 2 hrs at 4°C. Plate washing consisted of 3 x 100 µL per well washes of ELISA
35 wash buffer (T9039) (Sigma-Aldrich). Blocking was done for 1 hr at room temperature with (T6789)

1 Blocking Buffer (Sigma-Aldrich). Standards of recombinant human EPO (Cat no. 329871) (Merck
2 Millipore) were diluted to range from 8000-0 pg mL⁻¹ in sample dilution buffer (T6789 + 0.05%
3 Tween20) (Sigma-Aldrich). Samples were diluted to fall within the range of standard curve and 100 µL
4 incubated on the plate at 37°C for 1 hr. Rabbit Immunoglobulin-HRP (P0448) (Dako, Agilent) diluted
5 1:2000 was used for detection, 100 µL per well was incubated for 1 hr at room temperature. 100 µL of
6 development solution; 1.2 mL of 3,3',5,5'-Tetramethylbenzidin at 1 mg mL⁻¹ in DMSO, 2.4 µL 30 %
7 (v/v) hydrogen peroxide and 10.8 mL Phosphate-Citrate buffer (P4809) (Merck), was added to each
8 well and incubated for 30 minutes. The reaction was stopped by adding 100 µL 0.18 M H₂SO₄ to each
9 well. Protein concentration was determined by reading on a Multi-scan Go (Thermo Fischer Scientific)
10 and samples concentrations quantified using linear regression of the standard curve. Analysis consisted
11 of six technical replicates over three biological replicates.

12

13 Results

14 It has been previously reported that m⁶A motifs are significantly enriched in known circRNAs (Yang
15 et al., 2017). In their study, Yang et al., (2017) demonstrated dramatic increases in the translation
16 efficiency of circular mRNAs containing m⁶A motifs upstream of a reporter-gene start codon in direct
17 comparison to an A to T mutant and to a no adenosine control (No A CTRL). To investigate the potential
18 of m⁶A motifs improving the production efficiency of recombinant protein therapeutics in CHO cells,
19 we cloned three variants up-stream of a recombinant human Erythropoietin (rhEPO) open reading frame
20 (Fig. 1).

21 The three transcript variants; No A – CTRL, m⁶T and m⁶A were assessed by transient batch performance
22 in a CHO-K1 host. There was no significant difference in peak cell density between the transcript
23 variants and un-transfected (CHO-K1) and transfection reagent only (vehicle) controls (Fig. 2a). Nor
24 were there any deleterious effects on cell viability (Fig. 2b). Secreted EPO was monitored by ELISA of
25 culture supernatant harvested at 48 hr intervals. Cell specific productivity (Qp) was highest in the m⁶A
26 variant (Fig. 2c). The mean Qp of CHO-K1 cells was improved to (9.31 pg cell⁻¹ day⁻¹) with m⁶A from
27 (3.84 pg cell⁻¹ day⁻¹) in the No A control (p = 0.00048) and (3.56 pg cell⁻¹ day⁻¹) m⁶T (p = 0.00019).
28 Accordingly, mean EPO titer was improved significantly in the m⁶A variant at all time points of analysis
29 over both m⁶T and No A controls (Fig. 2d). The m⁶A construct increased the mean secreted EPO titer
30 to (13.6 µg mL⁻¹) from that of m⁶T (5.5 µg mL⁻¹) (p = 0.000487) and No A (5.7 µg mL⁻¹) (p = 0.000185)
31 at 48 hrs into culture (Fig. 2d). Expression of EPO mRNA with the m⁶A variant culminated in a final
32 increase at 144 hrs of 2.61-fold over m⁶T (p = 0.0042) and 2.84-fold over the No A control (p = 0.0029)
33 (Fig. 2d).

1 The exact function of m⁶A in eukaryotic translation is not fully understood with independent reports
2 describing its role in an mRNA's translation efficiency (Wang et al., 2015) and mRNA turnover or
3 stability (Wang et al., 2014; Du et al., 2016; Huang et al., 2018). The vectors used in this study drive
4 the expression of a resistance gene Hygromycin-B-phosphotransferase (HYG) under a PKG promoter.
5 Relative quantification (RQ) of HYG mRNA was assessed at 48, 96 and 144hrs and normalized to that
6 of the No A control at each time point with respect to the endogenous control Gapdh in all cases (Fig.
7 3a). There was no significant difference between any of the three constructs at any time point indicating
8 similar transfection efficiencies in all cases (Fig. 3a). The relative EPO mRNA abundance was 4.14-
9 fold ($p = 1.39 \times 10^{-5}$) and 4.99-fold ($p = 1.09 \times 10^{-5}$) higher with m⁶T and m⁶A, respectively over the No
10 A control construct at 48hrs (Fig. 3b). Relative to the No A control at each time point the m⁶T transcript
11 variant remained higher with a 4.16-fold ($p = 7.1 \times 10^{-5}$) and 3.45-fold ($p = 1.76 \times 10^{-6}$) increase in mRNA
12 abundance at 96 and 144hr time points respectively (Fig. 3b). Similarly, EPO mRNA abundance in the
13 m⁶A variant remained higher than the No A control with a 3.43-fold ($p = 0.00027$) and 3.84-fold ($p =$
14 1.46×10^{-5}) increase in mRNA abundance at 96 and 144hr time points respectively (Fig. 3b). With
15 transient transfection transgene expression decreases over time with the dilution of plasmid DNA as
16 cells divide. There was no significant difference in the rate of HYG mRNA abundance decreasing over
17 time between constructs (Fig. 3c). The Log₂ fold decrease in EPO mRNA abundance showed a
18 significantly different profile for the No A control, from (-0.5941) to (-0.015) with m⁶T ($p = 5.47 \times 10^{-6}$)
19 and (-0.0487) with m⁶A ($p = 4.3 \times 10^{-5}$) between 48 and 96 hrs into culture and from (-1.1084) in the No
20 A control to (-0.5284) for m⁶T and (-0.4013) m⁶A variants, ($p = 1.29 \times 10^{-5}$), ($p = 7.923 \times 10^{-6}$) respectively
21 between 96 and 144 hrs (Fig. 3d).

22 The three transcript variants used in this study contain subtle sequence differences, yet the relative
23 mRNA abundance and subsequent translation differed greatly. The secondary structure of all transcript
24 variants was analysed using RNAFold (Fig. 4a). There was similar structure present in the m⁶T and
25 m⁶A constructs, but these differed greatly from the distinct open structure of the No A control (Fig. 4a).
26 RNAComposer was used to predict the tertiary structure of these differing structures. The open loop
27 structured remained in the tertiary model of the No A control (Fig. 4b). Again, there was a highly similar
28 appearance between the m⁶T (Fig. 4c) and m⁶A variants (Fig. 4d).

29

30 Discussion

31 We present herein an observation of significantly improved recombinant titer with modifications of the
32 5' UTR of transgene mRNA. Employing a putative m⁶A motif previously reported to significantly
33 improve the cap-independent translation of circular mRNAs (Yang et al., 2017) in human cell lines.
34 Here we report it to have a similar effect on the translation of linear EPO mRNA in CHO-K1 cells with
35 higher Qp (Fig. 2c) resulting in increased secreted EPO titer (Fig. 2d). In transient batch culture we

1 observed no deleterious effects on peak cell density (Fig. 2a) or cell viability (Fig. 2b) associated with
2 any of the three transcript variants. It would be interesting to see if this positive impact on product titer
3 would hold through in stable mixed pools or clonal studies. Also, the sequence variants lack a consensus
4 Kozak motif, which is known to enhance translation. Future work should incorporate the use of a Kozak
5 sequence in the 5' UTR design. Simple addition of the Kozak motif may not be sufficient as the
6 inclusion of extra nucleotides would disrupt the 5' UTR secondary structure.

7 Perhaps the most interesting finding was the dramatic increase in EPO mRNA transcript variants
8 harbouring putative m⁶T and m⁶A motifs (Fig. 3b). Normalizing for transfection efficiency with HYG
9 mRNA, the m⁶T and m⁶A EPO mRNA variants had relative increases in abundance in the order of 4.14
10 and 4.99-fold, respectively over the No A control (Fig. 3b). The rate of m⁶T and m⁶A mRNA loss with
11 transient delivery was significantly reduced compared to that of the No A control (Fig. 3d). Given that
12 the loss of HYG mRNA was similar in all cases (Fig. 3c) and that RNA methylation is said to occur
13 post-transcriptionally (Fu et al., 2014), this suggests that the increase in mRNA abundance is due to
14 enhanced stability rather than improved transcription. Analysing the 5' UTR secondary folding of the
15 three transcript variants (Fig. 4) revealed a highly similar structure for both m⁶T and m⁶A but these two
16 differ greatly from the No A control. Variable translation efficiencies between the m⁶A and m⁶T suggest
17 that the differences can be attributed to the putative methylation of a single nucleotide substitution.
18 Recent evidence by Liu et al., (2015) described the presence of m⁶A conferred changes to mRNA
19 secondary structure. Their data suggests that methylation and demethylation resulted in dynamic
20 remodelling of local mRNA structures terming this “the m⁶A switch” (Liu et al., 2015). Restructuring
21 of the m⁶A transcript variant to include methylation is not possible with current RNA folding software
22 but this could explain the improved translation observed with the m⁶A over the m⁶T transcript variants.

23 To date, apart from circularization of transcript mRNA (Wesselhoeft et al., 2018), efforts to improve
24 the stability of linear transgene mRNA have yielded modest returns (Ferizi et al., 2015; Holtkamp et
25 al., 2006). The m⁶A motif used in this study contains a U/C at the -3 position which was found to be an
26 enriched motif from the consensus with IGF2BPs (Huang et al., 2018). As described by Huang et al.,
27 (2018), recognition of m⁶A by IGF2BPs enhanced mRNA stability. This could be an explanation for
28 why the putative m⁶A mRNA in this study had such improved relative mRNA abundance. Although we
29 must point out this may also stem from the highly stable hairpin structures formed in the m⁶T ($\Delta G = -$
30 32.30) and m⁶A ($\Delta G = -30.40$) variants over that of the No A control ($\Delta G = -17.90$). It is probable this
31 increased mRNA abundance is a combination of both for the m⁶A variant and can be attributed to the
32 highly stable hairpin in the m⁶T script.

33 Reports of reversible m⁶A writing, erasing and reading (Liu et al., 2014; Ping et al., 2014; Jia et al.,
34 2011; Zheng et al., 2013; Wang et al., 2014; Huang et al., 2018) point to this mechanism of post-
35 transcriptional regulation being highly tuneable. As of yet it has not been reported if m⁶A writers,

1 erasers and readers are dynamic between different stages of culture in CHO cells. If this is the case,
2 transgene mRNA encoding selective putative m⁶A motifs could be conditionally translated under
3 defined culture stages. With a report of targeted epigenetic editing of genomic DNA using a dCas9-
4 GCN4 peptide fusion (Morita et al., 2016) and newly reported ssRNA targeting CRISPR proteins,
5 Cas13b (Cox et al., 2017) the potential for targeted epigenetic regulation of transgene mRNA in
6 mammalian hosts could offer new components to the mammalian cell engineering toolbox.

7

8 **FUNDING**

9 This work was conducted under the financial support of Scientific Foundation of Ireland (SFI) grant numbers
10 [13/IA/1963] and [13/IA/1841].

1 References

- 2 Cox, D.B.T., Gootenberg, J.S., Abudayyeh, O.O., Franklin, B., Kellner, M.J., Joung, J. & Zhang, F. 2017, "RNA editing with
3 CRISPR-Cas13", *Science (New York, N.Y.)*, vol. 358, no. 6366, pp. 1019-1027.
- 4 Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-
5 Hirsch, J., Amariglio, N. & Kupiec, M. 2012, "Topology of the human and mouse m⁶A RNA methylomes revealed by
6 m⁶A-seq", *Nature*, vol. 485, no. 7397, pp. 201.
- 7 Du, H., Zhao, Y., He, J., Zhang, Y., Xi, H., Liu, M., Ma, J. & Wu, L. 2016, "YTHDF2 destabilizes m⁶A-containing RNA
8 through direct recruitment of the CCR4–NOT deadenylase complex", *Nature communications*, vol. 7, pp. 12626.
- 9 Ferizi, M., Leonhardt, C., Meggle, C., Aneja, M.K., Rudolph, C., Plank, C. & Rädler, J.O. 2015, "Stability analysis of
10 chemically modified mRNA using micropattern-based single-cell arrays", *Lab on a Chip*, vol. 15, no. 17, pp. 3561-
11 3571.
- 12 Fu, Y., Dominissini, D., Rechavi, G. & He, C. 2014, "Gene expression regulation mediated through reversible m⁶A RNA
13 methylation", *Nature Reviews Genetics*, vol. 15, no. 5, pp. 293-306.
- 14 Grens, A. & Scheffler, I.E. 1990, "The 5'- and 3'-untranslated regions of ornithine decarboxylase mRNA affect the translational
15 efficiency", *The Journal of biological chemistry*, vol. 265, no. 20, pp. 11810-11816.
- 16 He, C. 2010, "Grand challenge commentary: RNA epigenetics?", *Nature chemical biology*, vol. 6, no. 12, pp. 863.
- 17 Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Tureci, O. & Sahin, U. 2006, "Modification of
18 antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells",
19 *Blood*, vol. 108, no. 13, pp. 4009-4017.
- 20 Huang, H., Weng, H., Sun, W., Qin, X., Shi, H., Wu, H., Zhao, B.S., Mesquita, A., Liu, C. & Yuan, C.L. 2018, "Recognition
21 of RNA N⁶-methyladenosine by IGF2BP proteins enhances mRNA stability and translation", *Nature cell biology*, vol.
22 20, no. 3, pp. 285.
- 23 Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T. & Yang, Y. 2011, "N⁶-methyladenosine in
24 nuclear RNA is a major substrate of the obesity-associated FTO", *Nature chemical biology*, vol. 7, no. 12, pp. 885.
- 25 Kozak, M. 1986, "Influences of mRNA secondary structure on initiation by eukaryotic ribosomes", *Proceedings of the
26 National Academy of Sciences of the United States of America*, vol. 83, no. 9, pp. 2850-2854.
- 27 Leppek, K., Das, R. & Barna, M. 2018, "Functional 5' UTR mRNA structures in eukaryotic translation regulation and how to
28 find them", *Nature Reviews Molecular Cell Biology*, vol. 19, no. 3, pp. 158.
- 29 Li, F., Zhao, D., Wu, J. & Shi, Y. 2014, "Structure of the YTH domain of human YTHDF2 in complex with an m⁶A
30 mononucleotide reveals an aromatic cage for m⁶A recognition", *Cell research*, vol. 24, no. 12, pp. 1490.
- 31 Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z. & Deng, X. 2014, "A METTL3–METTL14
32 complex mediates mammalian nuclear RNA N⁶-adenosine methylation", *Nature chemical biology*, vol. 10, no. 2, pp.
33 93.
- 34 Liu, N., Dai, Q., Zheng, G., He, C., Parisien, M. & Pan, T. 2015, "N⁶-methyladenosine-dependent RNA structural switches
35 regulate RNA–protein interactions", *Nature*, vol. 518, no. 7540, pp. 560.
- 36 Liu, Y., Beyer, A. & Aebersold, R. 2016, "On the dependency of cellular protein levels on mRNA abundance", *Cell*, vol. 165,
37 no. 3, pp. 535-550.
- 38 Manning, K.S. & Cooper, T.A. 2017, "The roles of RNA processing in translating genotype to phenotype", *Nature Reviews
39 Molecular Cell Biology*, vol. 18, no. 2, pp. 102.
- 40 Meyer, K.D., Patil, D.P., Zhou, J., Zinoviev, A., Skabkin, M.A., Elemento, O., Pestova, T.V., Qian, S. & Jaffrey, S.R. 2015,
41 "5' UTR m⁶A promotes cap-independent translation", *Cell*, vol. 163, no. 4, pp. 999-1010.

- 1 Meyer, K.D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C.E. & Jaffrey, S.R. 2012, "Comprehensive analysis of mRNA
2 methylation reveals enrichment in 3' UTRs and near stop codons", *Cell*, vol. 149, no. 7, pp. 1635-1646.
- 3 Morita, S., Noguchi, H., Horii, T., Nakabayashi, K., Kimura, M., Okamura, K., Sakai, A., Nakashima, H., Hata, K. &
4 Nakashima, K. 2016, "Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic
5 domain fusions", *Nature biotechnology*, vol. 34, no. 10, pp. 1060.
- 6 Pichon, X., A Wilson, L., Stoneley, M., Bastide, A., A King, H., Somers, J. & E Willis, A. 2012, "RNA binding protein/RNA
7 element interactions and the control of translation", *Current Protein and Peptide Science*, vol. 13, no. 4, pp. 294-304.
- 8 Ping, X., Sun, B., Wang, L., Xiao, W., Yang, X., Wang, W., Adhikari, S., Shi, Y., Lv, Y. & Chen, Y. 2014, "Mammalian
9 WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase", *Cell research*, vol. 24, no. 2, pp.
10 177.
- 11 Shi, Z., Fujii, K., Kovary, K.M., Genuth, N.R., Röst, H.L., Teruel, M.N. & Barna, M. 2017, "Heterogeneous ribosomes
12 preferentially translate distinct subpools of mRNAs genome-wide", *Molecular cell*, vol. 67, no. 1, pp. 71-83. e7.
- 13 Simsek, D., Tiu, G.C., Flynn, R.A., Byeon, G.W., Leppek, K., Xu, A.F., Chang, H.Y. & Barna, M. 2017, "The mammalian
14 ribo-interactome reveals ribosome functional diversity and heterogeneity", *Cell*, vol. 169, no. 6, pp. 1051-1065. e18.
- 15 Stein, I., Itin, A., Einat, P., Skaliter, R., Grossman, Z. & Keshet, E. 1998, "Translation of vascular endothelial growth factor
16 mRNA by internal ribosome entry: implications for translation under hypoxia", *Molecular and cellular biology*, vol. 18,
17 no. 6, pp. 3112-3119.
- 18 Strahl, B.D. & Allis, C.D. 2000, "The language of covalent histone modifications", *Nature*, vol. 403, no. 6765, pp. 41.
- 19 Suzuki, M.M. & Bird, A. 2008, "DNA methylation landscapes: provocative insights from epigenomics", *Nature Reviews
20 Genetics*, vol. 9, no. 6, pp. 465.
- 21 Topisirovic, I., Svitkin, Y.V., Sonenberg, N. & Shatkin, A.J. 2011, "Cap and cap-binding proteins in the control of gene
22 expression", *Wiley Interdisciplinary Reviews: RNA*, vol. 2, no. 2, pp. 277-298.
- 23 Wang, X., Lu, Z., Gomez, A., Hon, G.C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q. & Jia, G. 2014, "N6-methyladenosine-
24 dependent regulation of messenger RNA stability", *Nature*, vol. 505, no. 7481, pp. 117.
- 25 Wang, X., Zhao, B.S., Roundtree, I.A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H. & He, C. 2015, "N6-
26 methyladenosine modulates messenger RNA translation efficiency", *Cell*, vol. 161, no. 6, pp. 1388-1399.
- 27 Wei, C., Gershowitz, A. & Moss, B. 1975, "Methylated nucleotides block 5' terminus of HeLa cell messenger RNA", *Cell*,
28 vol. 4, no. 4, pp. 379-386.
- 29 Wesselhoeft, R.A., Kowalski, P.S. & Anderson, D.G. 2018, "Engineering circular RNA for potent and stable translation in
30 eukaryotic cells", *Nature communications*, vol. 9, no. 1, pp. 2629.
- 31 Yang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., Jin, Y., Yang, Y., Chen, L. & Wang, Y. 2017, "Extensive translation
32 of circular RNAs driven by N6-methyladenosine", *Cell research*, vol. 27, no. 5, pp. 626-641.
- 33 Zheng, G., Dahl, J.A., Niu, Y., Fedorcsak, P., Huang, C., Li, C.J., Vågbo, C.B., Shi, Y., Wang, W. & Song, S. 2013, "ALKBH5
34 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility", *Molecular cell*, vol. 49, no. 1,
35 pp. 18-29.
- 36 Zhu, T., Roundtree, I.A., Wang, P., Wang, X., Wang, L., Sun, C., Tian, Y., Li, J., He, C. & Xu, Y. 2014, "Crystal structure of
37 the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine", *Cell research*, vol. 24, no.
38 12, pp. 1493.

39

1 **Figure Legends**

2 **Fig. 1** To investigate the effect of m⁶A on protein translation two putative m⁶A motifs (GGACT) were
3 inserted upstream of the human EPO open reading frame. **a** An A to T mutant was also tested (m⁶T)
4 and a no adenosine control (No A – CTRL). The sequence variants were cloned between HindIII and
5 XhoI (underlined) in a pcDNA3.1(+) Hygromycin backbone. The sites of methylation are indicated by
6 an asterisk and the EPO start codon highlighted in grey. **b** Nucleotide sequence of EPO used for
7 evaluation of different 5' UTR sequences.

8

9 **Fig. 2** CHO-K1 were transiently transfected with m⁶A motif variants and batch performance assessed.
10 **a** Cell growth post transfection is displayed as viable cells per mL of culture. **b** The % viability of
11 transfected cells during batch culture. **c** Cell specific productivity (Qp) of cells from 0 – 48 hr of culture.
12 **d** Secreted rhEPO titer ($\mu\text{g mL}^{-1}$) of transcript variants was measured using supernatant harvested every
13 48 hr of culture. The values are based on six technical replicates over three biological replicates
14 represented as the mean with standard deviation. Statistical analysis was done using a homoscedastic
15 student t-test, ($p \leq 0.05$ *, $p \leq 0.01$ **, $p \leq 0.001$ ***).


16

17 **Fig. 3** qRT-PCR analysis of total RNA harvested from CHO-K1 cells transiently expressing one of the
18 No A, m⁶T or m⁶A EPO mRNA transcript variants was run. **a** Relative quantification (RQ) of
19 Hygromycin (HYG) mRNA was used as a control of transfection efficiency. RQ was done using the
20 No A control as a calibrator at each time point of analysis. **b** RQ of EPO mRNA expression for all three
21 transcript variants was calculated with respect to the No A control at each time point of analysis. **c** The
22 rate of HYG mRNA loss over time during transient batch was calculated by the Log₂ fold reduction in
23 relative mRNA abundance at a time point with respect to the initial reading at t = 48 hrs. **d** The Log₂
24 fold reduction in EPO mRNA loss over transient batch culture. Values seen are the mean of three
25 biological replicates with error calculated by standard deviation. Statistical analysis was done using a
26 homoscedastic student t-test, ($p \leq 0.05$ *, $p \leq 0.01$ **, $p \leq 0.001$ ***).

27

28 **Fig. 4** The 5' UTR secondary and tertiary structures of the three sequence variants was evaluated. **a**
29 RNAFold predictions of the 5' UTR and full EPO open reading frame for each transcript variant.
30 Regions differing in secondary structure are circled. In all cases the difference occurred between the 5'
31 UTR and the first 50bp of the EPO open reading frame. The tertiary structure from the transcriptional
32 start site through the first 50bp of the open reading frame was analysed using RNAComposer and
33 PyMOL. **b** Tertiary structure of the No A CTRL 5' UTR. The EPO start codon is highlighted in hot
34 pink and the first 50bp of the open reading frame light pink. **c** Tertiary structure of the m⁶T 5' UTR
35 with m⁶T motifs coloured blue. **d** Tertiary structure of the m⁶A 5' UTR with putative m⁶A sites coloured
36 orange.

a



>No A - CTRL

AAGCTTCGGTGCCGGTGCCTCGAGATG...

>m⁶T

AAGCTT**GGTCTAAAGCGGTCTTGT**CTCGAGATG...


>m⁶A

AAGCTT**GGACTAAAGCGGACTTGT**CTCGAGATG...
* * *

b


ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCC
 CTGCTGTCGCTCCCTCTGGGCCTCCCAGTCCTGGGCGCCCCACCA
 CGCCTCATCTGTGACAGCCGAGTCCTGGAGAGGTACCTCTTGAG
 GCCAAGGAGGCCGAGAATATCACGACGGGCTGTGCTGAACACTGC
 AGCTTGAATGAGAATATCACTGTCCCAGACACCAAAGTTAATTC
 TATGCCTGGAAGAGGATGGAGGTCGGGCAGCAGGCCGTAGAAGTC
 TGGCAGGGCCTGGCCCTGCTGTCGGAAGCTGTCCTGCGGGGCCAG
 GCCCTGTTGGTCAACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTG
 CATGTGGATAAAGCCGTCAGTGGCCTTCGCAGCCTCACCCTCTG
 CTTCGGGCTCTGGGAGCCCAGAAGGAAGCCATCTCCCCTCCCGAT
 GCGGCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACTTTC
 CGAAACTCTTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTG
 AAGCTGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATATAA

1 Figure 2





2

1 Figure 3



2

1 Figure 4



2